Append Medical
Not specified, Israel· Est.
Implant‑free vacuum LAA occlusion device to prevent stroke in atrial fibrillation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $11.8M
AI Company Overview
Implant‑free vacuum LAA occlusion device to prevent stroke in atrial fibrillation.
Cardiovascular
Technology Platform
A transcatheter vacuum system that inverts and ligates the left atrial appendage without leaving any permanent implant, eliminating device‑related thromboembolism and peri‑device leakage.
Opportunities
Large unmet need for safer LAA occlusion and a growing NVAF patient base provide a multi‑billion‑dollar market; the implant‑free approach could capture patients unsuitable for existing devices.
Risk Factors
Regulatory approval hinges on demonstrating safety and efficacy in early trials; adoption may be slowed by entrenched implant‑based competitors and the need for clinician training.
Competitive Landscape
Key competitors include Watchman (Boston Scientific) and Amplatzer (Abbott); Append differentiates by eliminating permanent implants, thus removing DRT and PDL risks.